PURPOSE: The fact that up to 30% of established high-grade squamous intraepithelial lesions (HSIL) of the cervix regress spontaneously presents the opportunity to identify clinically relevant human papillomavirus (HPV) viral epitopes associated with disease outcome. Two human HPV antigens, E6 and E7, are functionally required for initiation and maintenance of cervical cancer precursor lesions and invasive cervical cancer. The identification and characterization of endogenously processed HPV antigenic epitopes in closely characterized patient cohorts will provide insight into the reasons for success or failure of therapeutic approaches. EXPERIMENTAL DESIGN: We characterized the HPV-16 E6/E7-specific T-cell epitopes using E6/E7 overlapping peptide pools with peripheral blood lymphocytes obtained from normal healthy donors. We then analyzed the difference in the HPV-16 T-cell immune responses in HPV-16+ HSIL patients with or without spontaneous regression of lesions using the statistical methods. RESULTS: We have identified an HPV-16 E7-specific CD4+ T-cell epitope [amino acids (aa) 71-85] that was restricted by HLA-DQB1*0201. Analysis of peripheral blood lymphocytes obtained from 14 HLA-DQB1*02 patients with HPV-16+ HSILs showed that the HPV-16+ E7 peptide (aa 71-85)-specific CD4+ T-cell immune response was significantly higher in the group of patients with regression compared with the patients without regression (P value <0.05). CONCLUSIONS: The HPV-16 E7 peptide-specific CD4+ T-cell immune response correlates with spontaneous regression of established HPV16+ HSILs. Thus, this E7 epitope may be useful for the characterization of HPV-specific immune responses in patients infected with HPV-16 or immunized with HPV vaccines.
PURPOSE: The fact that up to 30% of established high-grade squamous intraepithelial lesions (HSIL) of the cervix regress spontaneously presents the opportunity to identify clinically relevant humanpapillomavirus (HPV) viral epitopes associated with disease outcome. Two humanHPV antigens, E6 and E7, are functionally required for initiation and maintenance of cervical cancer precursor lesions and invasive cervical cancer. The identification and characterization of endogenously processed HPV antigenic epitopes in closely characterized patient cohorts will provide insight into the reasons for success or failure of therapeutic approaches. EXPERIMENTAL DESIGN: We characterized the HPV-16 E6/E7-specific T-cell epitopes using E6/E7 overlapping peptide pools with peripheral blood lymphocytes obtained from normal healthy donors. We then analyzed the difference in the HPV-16 T-cell immune responses in HPV-16+ HSILpatients with or without spontaneous regression of lesions using the statistical methods. RESULTS: We have identified an HPV-16 E7-specific CD4+ T-cell epitope [amino acids (aa) 71-85] that was restricted by HLA-DQB1*0201. Analysis of peripheral blood lymphocytes obtained from 14 HLA-DQB1*02 patients with HPV-16+ HSILs showed that the HPV-16+ E7 peptide (aa 71-85)-specific CD4+ T-cell immune response was significantly higher in the group of patients with regression compared with the patients without regression (P value <0.05). CONCLUSIONS: The HPV-16 E7 peptide-specific CD4+ T-cell immune response correlates with spontaneous regression of established HPV16+ HSILs. Thus, this E7 epitope may be useful for the characterization of HPV-specific immune responses in patients infected with HPV-16 or immunized with HPV vaccines.
Authors: Annemieke de Jong; Sjoerd H van der Burg; Kitty M C Kwappenberg; Jeanette M van der Hulst; Kees L M C Franken; Annemieke Geluk; Krista E van Meijgaarden; Jan Wouter Drijfhout; Gemma Kenter; Pieter Vermeij; Cornelis J M Melief; Rienk Offringa Journal: Cancer Res Date: 2002-01-15 Impact factor: 12.701
Authors: Anna S Kadish; Patrick Timmins; Yuexian Wang; Gloria Y F Ho; Robert D Burk; John Ketz; Wu He; Seymour L Romney; Anne Johnson; Ruth Angeletti; Maria Abadi Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-05 Impact factor: 4.254
Authors: Annemieke de Jong; Mariëtte I E van Poelgeest; Jeanette M van der Hulst; Jan Wouter Drijfhout; Gert Jan Fleuren; Cornelis J M Melief; Gemma Kenter; Rienk Offringa; Sjoerd H van der Burg Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah Journal: J Natl Cancer Inst Date: 1995-06-07 Impact factor: 13.506
Authors: Dominic E Warrino; Walter C Olson; William T Knapp; Meera I Scarrow; Lori J D'Ambrosio-Brennan; Richard S Guido; Robert P Edwards; W Martin Kast; Walter J Storkus Journal: Clin Cancer Res Date: 2004-05-15 Impact factor: 12.531
Authors: P P Ip; A Boerma; M Walczak; K Oosterhuis; J B Haanen; T N Schumacher; H W Nijman; T Daemen Journal: Gene Ther Date: 2015-03-26 Impact factor: 5.250
Authors: Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim Journal: Sci Transl Med Date: 2012-10-10 Impact factor: 17.956
Authors: Hongliang Liu; Jian Wang; Robert Yu; Sanjay Shete; Erich M Sturgis; Guojun Li; Kristina R Dahlstrom; Zhensheng Liu; Christopher I Amos; Qingyi Wei Journal: Cancer Res Date: 2020-04-10 Impact factor: 12.701
Authors: I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet Journal: Clin Exp Immunol Date: 2009-07-30 Impact factor: 4.330
Authors: Trinidad Garcia-Iglesias; Alicia Del Toro-Arreola; Benibelks Albarran-Somoza; Susana Del Toro-Arreola; Pedro E Sanchez-Hernandez; Maria Guadalupe Ramirez-Dueñas; Luz Ma Adriana Balderas-Peña; Alejandro Bravo-Cuellar; Pablo C Ortiz-Lazareno; Adrian Daneri-Navarro Journal: BMC Cancer Date: 2009-06-16 Impact factor: 4.430